Form 4: VolitionRX Officer Acquires 50,000 Shares of Common Stock

Jacob Vincent Micallef, Chief Scientific Officer of VolitionRX Ltd, purchased 50,000 shares of common stock at $0.43 per share on May 19, 2025.

Summary

• On May 19, 2025, Jacob Vincent Micallef, the Chief Scientific Officer of VolitionRX Ltd (VNRX), acquired 50,000 shares of common stock.
• The purchase price was $0.43 per share.
• Following the transaction, Micallef directly owns 426,033 shares of common stock.
• Micallef also indirectly owns 55,000 shares through his spouse and 38,113 shares through Borlaug Limited, where he is a controlling director.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying can be a positive signal, but the impact depends on the size of the purchase relative to the officer's existing holdings and the overall market context.

Positives

• The purchase of shares by a company officer can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's sentiment and confidence in the company's performance.

Stakeholder Impact

• The stock purchase by a company officer could positively influence shareholder sentiment.

Key Dates

Keywords

VolitionRX, VNRX, insider trading, Form 4, Micallef, Chief Scientific Officer, stock purchase, beneficial ownership